LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients

Katharine Abbott-Banner (London, United Kingdom), Dave Singh, Katharine Abbott-Banner, Kenneth Newman

Source: International Congress 2016 – Late-breaking topics in airways disease

Session: Late-breaking topics in airways disease
Session type: Oral Presentation
Number: 1970

Disease area: Airway diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Katharine Abbott-Banner (London, United Kingdom), Dave Singh, Katharine Abbott-Banner, Kenneth Newman. LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients. Eur Respir J 2016; 48: Suppl. 60, 1970

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
LATE-BREAKING ABSTRACT: Novel inhaled ROR/c inhibitor for potential treatment of COPD Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
LATE-BREAKING ABSTRACT: Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique “first-in-class” drug for the treatment of COPD & asthma Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013
Lung function, symptoms and prescription of inhaled steroids and long acting β2 agonists in patients managed by an integrated COPD team Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015
QVA149 provides superior peak lung function in patients with COPD Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Comparison of protective effect of bronchodilators in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
LATE-BREAKING ABSTRACT: PT003, a novel co-suspension MDI glycopyrronium/formoterol fixed-dose combination is superior to monocomponents in patients with COPD Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
Effect of dual bronchodilation with indacaterol/glycopirronium on small airways resistance in patients with stable COPD Source: International Congress 2016 – Non-inflammatory COPD monitoring Year: 2016
RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
Are COPD patients with chronic dyspnea and attending pulmonary rehabilitation treated with dual bronchodilatation or not? Source: International Congress 2016 – Best abstracts in COPD management Year: 2016